Janux Therapeutics, Inc. (JANX)
13.30
-0.33
(-2.42%)
USD |
NASDAQ |
Mar 27, 13:51
Janux Therapeutics Cash from Investing (Quarterly) : 29.54M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | -1.458B |
| EyePoint Plc | -74.67M |
| Madrigal Pharmaceuticals, Inc. | 27.58M |
| CorMedix, Inc. | 3.297M |
| Viking Therapeutics, Inc. | 75.61M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -28.54M |
| Cash from Financing (Quarterly) | 2.944M |
| Free Cash Flow | -83.28M |
| Free Cash Flow Per Share (Quarterly) | -0.461 |
| Free Cash Flow to Equity (Quarterly) | -28.13M |
| Free Cash Flow to Firm (Quarterly) | -28.65M |
| Free Cash Flow Yield | -10.10% |